The goals of this core are to provide laboratory support for in situ (primarily immunohistochemical) assays, serve as a collaborator/consultant in investigations of breast cancer biology/pathology, and facilitate translational applications of potentially important assays on breast tissue samples to investigate their clinical significance. A major responsibility of this core is to work closely with Dr. Smith's project to investigate markers which may identify DClS with a high risk of recurrence or invasion. Markers associated with either tissue invasion or metastasis, as well as cellular proliferation (i.e. factors which affect the cell cycle, cellular division or death) will be emphasized. The expression, or lack thereof, of these will be investigated in benign, premalignant, malignant in situ and invasive breast epithelium. Markers which can be associated with an aggressive phenotype of ductal carcinoma in situ (DCIS) will be tested on retrospectively accrued cases of DCIS with or without disease recurrence and/or progression. This core will also serve as an additional tissue resource providing fixed-embedded archival human breast tissues containing specific lesions. Review of breast pathology, histologic and immunohistologic slide interpretation will also be provided.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058207-08S3
Application #
6502914
Study Section
Project Start
1999-08-01
Project End
2002-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2001
Total Cost
$206,819
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications